{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:52:50Z","timestamp":1791211970093,"version":"4.1.0"},"reference-count":25,"publisher":"Bioscientifica","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The adrenocortical-specific PET tracer [11C]metomidate (11C-MTO) shows high diagnostic accuracy in adrenocortical carcinoma (ACC), but complex radiochemistry and short half-life limit clinical implementation. The novel tracer para-chloro-2-[18F]fluoroethyletomidate (18F-CETO) may enable broader use. In this bicentric study, 20 ACC patients underwent PET\/CT with 18F-CETO and [18F]fluoro-2-deoxy-D-glucose (18F-FDG), with 235 lesions identified. 18F-CETO detected more lesions than 18F-FDG at initial staging in 5\/13 patients, whereas fewer lesions were detected at re-staging in 5\/7 patients (P = 0.002). A further 70 patients with 18F-CETO or 11C-MTO-PET\/CT and an anatomical imaging reference were used to explore the utility of adrenocortical imaging. Three adrenocortical imaging phenotypes were defined: homogeneous-high (n = 71), homogeneous-low (n = 11), and heterogeneous (n = 8), which showed differences in overall survival in exploratory analyses. Tumors were characterized by RNA sequencing and immunohistochemistry showing correlation between tracer-uptake to CYP11B1 expression and adrenocortical differentiation. These findings suggest a potential role for 18F-CETO in ACC phenotyping and initial staging.<\/jats:p>","DOI":"10.1530\/erc-26-0314","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:10:40Z","timestamp":1790169040000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["18F-CETO in adrenocortical carcinoma: first clinical-translational study of an adrenocortical-targeting PET tracer"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5363-8313","authenticated-orcid":true,"given":"Adam","family":"Edholm","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Uppsala University 1 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-6754","authenticated-orcid":true,"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University 1 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"MacFarlane","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cambridge University Hospitals NHS Foundation Trust 2 , ,","place":["Cambridge, UK"]},{"name":"Cambridge Endocrine Molecular Imaging Group, University of Cambridge 3 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"\u00c5kerstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University 4 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Senanayake","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cambridge University Hospitals NHS Foundation Trust 2 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Welin","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University 1 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Hegedus","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University 5 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heok K","family":"Cheow","sequence":"additional","affiliation":[{"name":"Cambridge Endocrine Molecular Imaging Group, University of Cambridge 3 , ,","place":["Cambridge, UK"]},{"name":"Department of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust 6 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieva","family":"Lase","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University 1 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"St\u00e5lberg","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University 4 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-5816","authenticated-orcid":true,"given":"Azita","family":"Monazzam","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University 1 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gillett","sequence":"additional","affiliation":[{"name":"Cambridge Endocrine Molecular Imaging Group, University of Cambridge 3 , ,","place":["Cambridge, UK"]},{"name":"Department of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust 6 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Aloj","sequence":"additional","affiliation":[{"name":"Cambridge Endocrine Molecular Imaging Group, University of Cambridge 3 , ,","place":["Cambridge, UK"]},{"name":"Department of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust 6 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hellman","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University 4 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Wargelius","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University 1 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Tadross","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust 7 , ,","place":["Cambridge, UK"]},{"name":"Medical Research Council Metabolic Diseases Unit, Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge 8 , ,","place":["Cambridge, UK"]},{"name":"Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust 9 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Antoni","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Uppsala University 10 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Aigbirhio","sequence":"additional","affiliation":[{"name":"Wolfson Brain Imaging Centre, University of Cambridge 11 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Skogseid","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University 1 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gurnell","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cambridge University Hospitals NHS Foundation Trust 2 , ,","place":["Cambridge, UK"]},{"name":"Cambridge Endocrine Molecular Imaging Group, University of Cambridge 3 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5704-8817","authenticated-orcid":true,"given":"Samuel","family":"Backman","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University 4 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Sundin","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Uppsala University 4 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9938-8819","authenticated-orcid":true,"given":"Ruth T","family":"Casey","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Cambridge University Hospitals NHS Foundation Trust 2 , ,","place":["Cambridge, UK"]},{"name":"Cambridge Endocrine Molecular Imaging Group, University of Cambridge 3 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0677-4894","authenticated-orcid":true,"given":"Joakim","family":"Crona","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University 1 , ,","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026100510013445700_bib1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100510013445700_bib2","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026100510013445700_bib3","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"2026100510013445700_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/ijnm.ijnm_4_22","article-title":"Fluoro-2-deoxyglucose-positron emission tomography\/computed tomography in the diagnosis and management of adrenocortical carcinoma: a 10-year experience from a tertiary care institute","volume":"37","author":"Krishnaraju","year":"2022","journal-title":"Indian J Nucl Med"},{"key":"2026100510013445700_bib5","first-page":"263","article-title":"Diagnostic role of 18F-fluorodeoxyglucose positron-emission tomography\/computed tomography in restaging renal cell carcinoma","volume":"68","author":"Ozturk","year":"2016","journal-title":"Minerva Urol Nefrol"},{"key":"2026100510013445700_bib6","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1007\/s12020-024-03695-6","article-title":"Prognostic role of quantitative [18F]FDG PET\/CT parameters in adrenocortical carcinoma","volume":"84","author":"Schl\u00f6telburg","year":"2024","journal-title":"Endocrine"},{"key":"2026100510013445700_bib7","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1007\/s00259-014-2834-3","article-title":"Impact of 18F-FDG PET\/CT on the management of adrenocortical carcinoma: analysis of 106 patients","volume":"41","author":"Takeuchi","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100510013445700_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/RLU.0000000000004593","article-title":"Positive correlation between 18 F-FDG uptake and tumor-proliferating antigen Ki-67 expression in adrenocortical carcinomas","volume":"48","author":"Lib\u00e9","year":"2023","journal-title":"Clin Nucl Med"},{"key":"2026100510013445700_bib9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100510013445700_bib10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma \u2013 towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"2026100510013445700_bib11","first-page":"982","article-title":"In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors","volume":"39","author":"Bergstr\u00f6m","year":"1998","journal-title":"J Nucl Med"},{"key":"2026100510013445700_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105735","article-title":"Combined [18F]Fluorodeoxyglucose PET and [123I]Iodometomidate-SPECT for diagnostic evaluation of indeterminate adrenal neoplasias-the cross-sectional diagnostic test accuracy study FAMIAN","volume":"116","author":"Hahner","year":"2025","journal-title":"EBioMedicine"},{"key":"2026100510013445700_bib13","first-page":"972","article-title":"Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG","volume":"45","author":"Minn","year":"2004","journal-title":"J Nucl Med"},{"key":"2026100510013445700_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00259-021-05477-y","article-title":"Novel CYP11B-ligand [123\/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience","volume":"49","author":"Heinze","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100510013445700_bib15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejrad.2007.10.024","article-title":"Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas","volume":"69","author":"Hennings","year":"2009","journal-title":"Eur J Radiol"},{"key":"2026100510013445700_bib16","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.7150\/ijms.51206","article-title":"Para-chloro-2-[18F]fluoroethyl-etomidate: a promising new PET radiotracer for adrenocortical imaging","volume":"18","author":"Silins","year":"2021","journal-title":"Int J Med Sci"},{"key":"2026100510013445700_bib17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00259-022-05957-9","article-title":"First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours","volume":"50","author":"Silins","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100510013445700_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/0284186X.2017.1337926","article-title":"U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden","volume":"57","author":"Glimelius","year":"2018","journal-title":"Acta Oncol"},{"key":"2026100510013445700_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41591-022-02114-5","article-title":"[11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial","volume":"29","author":"Wu","year":"2023","journal-title":"Nat Med"},{"key":"2026100510013445700_bib20","first-page":"275","article-title":"PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate","volume":"41","author":"Bergstr\u00f6m","year":"2000","journal-title":"J Nucl Med"},{"key":"2026100510013445700_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00259-002-1025-9","article-title":"11C-metomidate PET imaging of adrenocortical cancer","volume":"30","author":"Khan","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100510013445700_bib22","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1111\/bcp.14721","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026100510013445700_bib23","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2967\/jnumed.120.257915","article-title":"68Ga-PSMA-11 PET\/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma","volume":"62","author":"Hirmas","year":"2021","journal-title":"J Nucl Med"},{"key":"2026100510013445700_bib24","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2967\/jnumed.122.265245","article-title":"68Ga-FAPI PET\/CT interobserver agreement on tumor assessment: an international multicenter prospective study","volume":"64","author":"Mei","year":"2023","journal-title":"J Nucl Med"},{"key":"2026100510013445700_bib25","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0314\/525658\/erc-26-0314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0314\/525658\/erc-26-0314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:01:45Z","timestamp":1791208905000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/10\/e260314\/78256\/18F-CETO-in-adrenocortical-carcinoma-first"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-26-0314","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"e260314"}}